# ![@MazeInBiotech Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1428386285023076363.png) @MazeInBiotech Maze Therapeutics

Maze Therapeutics posts on X about $maze, ceo, in the, community the most. They currently have [---] followers and [--] posts still getting attention that total [--] engagements in the last [--] hours.

### Engagements: [--] [#](/creator/twitter::1428386285023076363/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1428386285023076363/c:line/m:interactions.svg)

- [--] Week [---] +1,000%
- [--] Month [---] +940%
- [--] Months [---] +41%
- [--] Year [-----] -64%

### Mentions: [--] [#](/creator/twitter::1428386285023076363/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1428386285023076363/c:line/m:posts_active.svg)


### Followers: [---] [#](/creator/twitter::1428386285023076363/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1428386285023076363/c:line/m:followers.svg)

- [--] Week [---] no change
- [--] Month [---] -0.17%
- [--] Months [---] +9.80%
- [--] Year [---] +28%

### CreatorRank: undefined [#](/creator/twitter::1428386285023076363/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1428386285023076363/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks)  [finance](/list/finance) 

**Social topic influence**
[$maze](/topic/$maze) #6, [ceo](/topic/ceo), [in the](/topic/in-the), [community](/topic/community), [for the](/topic/for-the), [kidney](/topic/kidney), [journey](/topic/journey), [we are](/topic/we-are), [ipo](/topic/ipo), [major](/topic/major)

**Top accounts mentioned or mentioned by**
[@asnkidneys](/creator/undefined) [@nasdaqexchange](/creator/undefined) [@nkf](/creator/undefined) [@endpts](/creator/undefined) [@bradloncar](/creator/undefined) [@sullycnbc](/creator/undefined) [@cnbcs](/creator/undefined) [@powerlunch](/creator/undefined) [@npkuainfo](/creator/undefined) [@guggenheimptnrs](/creator/undefined) [@anirvan0419](/creator/undefined) [@kkidneys](/creator/undefined) [@sciencemagazine](/creator/undefined) [@biotechtvs](/creator/undefined) [@jefferiesevents](/creator/undefined) [@biotechtvhqs](/creator/undefined) [@shionogijp](/creator/undefined) [@biotechtv](/creator/undefined) [@npkua_info](/creator/undefined) [@danbudwick](/creator/undefined)

**Top assets mentioned**
[Maze Therapeutics, Inc. (MAZE)](/topic/$maze)
### Top Social Posts
Top posts by engagements in the last [--] hours

"We're honored to be recognized as part of this year's @endpts [--] awards. Thank you to John Carroll and the Endpoints team for recognizing the incredible progress our exceptional & dedicated team has made. (1/2)"  
[X Link](https://x.com/MazeInBiotech/status/1704844032571056331)  2023-09-21T13:04Z [---] followers, [---] engagements


"Maze attended the @endpts [--] ceremony to accept the award on behalf of the entire team. Listen as Harold Bernstein our President of R&D briefly discusses Mazes programs and the incredible potential of the platform to impact common diseases. Watch here:"  
[X Link](https://x.com/MazeInBiotech/status/1709973791835566095)  2023-10-05T16:48Z [---] followers, [---] engagements


"We're thrilled to share our manuscript "Small-molecule inhibition of GYS1 for the treatment of Pompe disease and other glycogen storage disorders featured as the cover story of the latest @ScienceMagazine. Congrats to our team on this exciting research"  
[X Link](https://x.com/MazeInBiotech/status/1747999440722391204)  2024-01-18T15:08Z [---] followers, [----] engagements


"Today on #RareDiseaseDay we join the #raredisease community to raise awareness for #Pompe patients. Pompe disease occurs when glycogen builds up in the bodys cells causing progressive muscle weakness and painful side effects for patients which experience the disease. (1/2)"  
[X Link](https://x.com/MazeInBiotech/status/1763204958319415417)  2024-02-29T14:09Z [---] followers, [---] engagements


"Read more about Pompe disease by clicking the link and explore the NORD site to learn how you can make a difference for patients living with rare diseases"  
[X Link](https://x.com/MazeInBiotech/status/1763204960177492296)  2024-02-29T14:09Z [---] followers, [--] engagements


"We are pleased to announce that the first participant has been dosed in our Phase [--] clinical trial evaluating MZE782. MZE782 is a potentially first-in-class oral small molecule targeting the solute transporter SLC6A19 and has the potential to address chronic #kidneydisease (CKD) patients.Learn more about the MZE782 program here: https://www.businesswire.com/news/home/20241001734162/en/Maze-Therapeutics-Initiates-Phase-1-First-in-Human-Trial-Evaluating-MZE782-as-a-Potential-Treatment-for-Chronic-Kidney-Disease"  
[X Link](https://x.com/MazeInBiotech/status/1841095359025619299)  2024-10-01T12:38Z [---] followers, [----] engagements


"Inclusion allows all diversity to be valued and respected. We all benefit from more diverse teams. Karol Estrada MazeVice President of Translational Genomics In celebration of #HispanicHeritageMonthwe heard from Mazer Karol Estrada as he shared the importance of #diversity within teams. We also welcomed Sammantha co-founder of Inessence Dance Company for an exciting salsa dance lesson. Our team enjoyed learning the basics of this dance appreciating its rich cultural significance and celebrating the blend of U.S. Latin and Hispanic traditions"  
[X Link](https://x.com/MazeInBiotech/status/1846582883290411021)  2024-10-16T16:04Z [---] followers, [--] engagements


"Today we announced the completion of a $115 million financing with new investors Frazier Life Sciences Deep Track Capital Janus Henderson Investors and Logos Capital as well as continued support from our existing investors. The resources provided by this financing will allow us to optimize our upcoming Phase [--] clinical trials and further explore the potential of MZE829 and MZE782 for a wide range of patients. This support marks an important step in our growth as a company and for the patients we aim to serve. Read more here:"  
[X Link](https://x.com/MazeInBiotech/status/1863931099262357597)  2024-12-03T12:59Z [---] followers, [----] engagements


"We're excited to announce the pricing of our IPO and listing on @NasdaqExchange as $MAZE. This milestone is a testament to the dedication of our incredible team the trust of our partners and the belief in our vision to make a lasting impact for patients. This exceptional progress from the team over the past several years marks the beginning of an exciting new chapter in our mission to harness the power of human genetics to transform the lives of patients. https://mazetx.com/maze-therapeutics-announces-pricing-of-upsized-initial-public-offering/"  
[X Link](https://x.com/MazeInBiotech/status/1885327182488027391)  2025-01-31T14:00Z [---] followers, [---] engagements


"Our CEO Jason Coloma recently sat down with @BiotechTV's @BradLoncar to discuss the latest on our development programs including our lead program MZE829 for APOL1 #kidneydisease the significant unmet need for patients and how were working to bring forward new treatment options byharnessing the power of human genetics.  : @MazeInBiotech which had its IPO earlier this year is using insights from genetics to develop small molecules - its most advanced program is for a genetic kidney disease. $MAZE Full video: https://t.co/PiucSzJzG0 https://t.co/yLUeFIwteA  : @MazeInBiotech which had its IPO"  
[X Link](https://x.com/MazeInBiotech/status/1955273047663100003)  2025-08-12T14:19Z [---] followers, [---] engagements


"We recently joined the Tampa Bay #KidneyWalk hosted by the @nkf to help raise awareness and support for the millions of people impacted by #kidneydisease"  
[X Link](https://x.com/anyuser/status/1973021952077111654)  2025-09-30T13:47Z [---] followers, [---] engagements


"Listen in as we present a corporate overview on Maze at the @JefferiesEvents Healthcare Conference on Thursday June [--] [----] at 11:30 a.m. ET. A webcast & replay of the presentation will be available on our website. #JefferiesHealthcare https://www.businesswire.com/news/home/20230601005070/en/Maze-Therapeutics-to-Participate-in-the-2023-Jefferies-Healthcare-Conference https://www.businesswire.com/news/home/20230601005070/en/Maze-Therapeutics-to-Participate-in-the-2023-Jefferies-Healthcare-Conference"  
[X Link](https://x.com/MazeInBiotech/status/1664253062817488899)  2023-06-01T12:50Z [---] followers, [---] engagements


"We had a great week at #JPM24 sharing our story and progress across our portfolio of small molecule precision medicines while learning about other exciting developments from peers. Events like these are a powerful reminder of the impactful work being done forfor patients. (1/2)"  
[X Link](https://x.com/MazeInBiotech/status/1747281426599256398)  2024-01-16T15:35Z [---] followers, [---] engagements


"We're pleased to announce our participation and attendance in upcominginvestor conferences. View today's announcement https://www.businesswire.com/news/home/20240226227699/en/Maze-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences https://www.businesswire.com/news/home/20240226227699/en/Maze-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences"  
[X Link](https://x.com/MazeInBiotech/status/1762131227241222451)  2024-02-26T15:03Z [---] followers, [---] engagements


"We are pleased to announce the first patient has been dosed in our Phase [--] clinical trial the HORIZON Study of MZE829 in patients with APOL1 #kidneydisease (AKD). MZE829 is an oral small molecule #APOL1 inhibitor that we are advancing as a potential treatment for people living with AKD a subset of chronic kidney disease estimated to affect over one million patients in the U.S. alone.The HORIZON study isdesigned to include a broad spectrum of patients across multiple cohorts reflecting the diverse characteristics of AKD.Read more here:"  
[X Link](https://x.com/MazeInBiotech/status/1887850783267344834)  2025-02-07T13:07Z [---] followers, [----] engagements


"Our team recently sponsored the Huntsville Community Health Fair an event focused on expanding access to free health screenings wellness resources and preventative care tools. Events like these play a critical role in connecting people with the support they need to take control of their health especially in communities that are often underserved. Early detection can make a world of difference for individuals at risk of #kidneydisease yet too often access to the right screenings and resources comes too late. At Maze we believe that equitable access to care education and support is essential"  
[X Link](https://x.com/MazeInBiotech/status/1945475488832475392)  2025-07-16T13:27Z [---] followers, [---] engagements


"Today we reported financial results for the first quarter ended March [--] [----] and reiterated upcoming milestones. Read the full announcement here: https://ir.mazetx.com/news-releases/news-release-details/maze-therapeutics-reports-first-quarter-2025-financial-results https://ir.mazetx.com/news-releases/news-release-details/maze-therapeutics-reports-first-quarter-2025-financial-results"  
[X Link](https://x.com/MazeInBiotech/status/1922747294971035894)  2025-05-14T20:14Z [---] followers, [---] engagements


"In preclinical studies administration of Mazes APOL1 inhibitor has been well tolerated and has led to improvement of albuminuria in both chronic and acute models of APOL1 #kidney disease. Read more about our progress with MZE829 here: (2/2) https://www.businesswire.com/news/home/20231214617201/en/Maze-Therapeutics-Announces-Initiation-of-Dosing-in-Phase-1-Trial-Evaluating-MZE829-a-Novel-Oral-APOL1-Inhibitor-as-a-Potential-Treatment-for-APOL1-Kidney-Disease"  
[X Link](https://x.com/MazeInBiotech/status/1735292612645466187)  2023-12-14T13:36Z [---] followers, [---] engagements


"At #JPM26 Join us this morning at 8:15 a.m. PT for our presentation. Were looking forward to kicking off the new year at #JPM26. CEO Jason Coloma Ph.D. will present on Monday January [--] at 8:15 a.m. PT. A live webcast of the event will be available in the Investors section of our website and archived for [--] days following the presentation. https://t.co/AvZW35s4Ub Were looking forward to kicking off the new year at #JPM26. CEO Jason Coloma Ph.D. will present on Monday January [--] at 8:15 a.m. PT. A live webcast of the event will be available in the Investors section of our website and archived"  
[X Link](https://x.com/anyuser/status/2010710803230368075)  2026-01-12T13:49Z [---] followers, [---] engagements


"One year ago Maze took a major step forward with our debut as a public company. This week we celebrated that milestone and oursubsequentsuccess ringing the @NasdaqExchange opening bell in honor of our one-year #IPOanniversary.Wereproud of whatweve accomplished together and energized bywhatsahead as we continue to execute in dedication to transforming the lives of patients living with kidney and metabolic diseases. $MAZE https://twitter.com/i/web/status/2016894760871473286 https://twitter.com/i/web/status/2016894760871473286"  
[X Link](https://x.com/anyuser/status/2016894760871473286)  2026-01-29T15:22Z [---] followers, [---] engagements


"We are pleased to announce an oversubscribed private placement of $150M today to further advance our pipeline of small molecule precision medicines for patients with kidney and metabolic diseases. Read the full announcement: https://ir.mazetx.com/news-releases/news-release-details/maze-therapeutics-announces-oversubscribed-1500-million-private https://ir.mazetx.com/news-releases/news-release-details/maze-therapeutics-announces-oversubscribed-1500-million-private"  
[X Link](https://x.com/anyuser/status/1966107453642183077)  2025-09-11T11:52Z [---] followers, [---] engagements


"Our CEO Jason Coloma joined @SullyCNBC on @CNBCs@PowerLunch to discuss Mazes recent progress and how were translating human genetics into new therapies across our pipeline. Chronic kidney disease remains a devastating condition with limited treatment options affecting millions of patients and families worldwide. At Maze were committed to advancing novel #smallmolecule #precisionmedicines designed to address the underlying drivers of #kidneydisease and metabolic disorders in meaningful ways. Watch the full interview:"  
[X Link](https://x.com/anyuser/status/1983278715539743168)  2025-10-28T21:04Z [---] followers, [---] engagements


"We are excited to announce that we will be presenting new data on our APOL1 #kidneydisease program during a poster session at @ASNKidneys Kidney Week on 11/4 at [--] a.m. ET. (1/2) https://www.businesswire.com/news/home/20231013971220/en/Maze-Therapeutics-to-Present-New-Data-for-APOL1-Kidney-Disease-in-Proprietary-Chronic-Preclinical-Model-Demonstrating-Reversal-of-Albuminuria https://www.businesswire.com/news/home/20231013971220/en/Maze-Therapeutics-to-Present-New-Data-for-APOL1-Kidney-Disease-in-Proprietary-Chronic-Preclinical-Model-Demonstrating-Reversal-of-Albuminuria"  
[X Link](https://x.com/MazeInBiotech/status/1712873256984666306)  2023-10-13T16:49Z [---] followers, [---] engagements


"The FTC has filed a complaint seeking to block Sanofis exclusive worldwide license agreement for Mazes glycogen synthase [--] (GYS1) program including clinical candidate MZE001. We respectfully disagree with this unprecedented decision and believe that. (1/2)"  
[X Link](https://x.com/MazeInBiotech/status/1734345619110826203)  2023-12-11T22:53Z [---] followers, 12.2K engagements


". the FTCs complaint could negatively impact our industry's ability to advance new medicines for patients in need. Read our statement here: (2/2) https://www.businesswire.com/news/home/20231211835372/en/Maze-Therapeutics-Announces-FTC-Action-Seeking-to-Block-Collaboration-and-License-Agreement-with-Sanofi-Regarding-MZE001-a-Potential-Oral-Substrate-Reduction-Therapy-for-Pompe-Disease"  
[X Link](https://x.com/MazeInBiotech/status/1734345621770039509)  2023-12-11T22:53Z [---] followers, [---] engagements


"Headed to #JPM24 Be sure to catch our CEO Jason Coloma present a company overview during the 42nd Annual Conference on Tuesday January [--] at [--] p.m. PT. We're looking forward to an exciting [----] for Maze https://www.businesswire.com/news/home/20240103872274/en/Maze-Therapeutics-to-Present-at-the-42nd-Annual-J.P.-Morgan-Healthcare-Conference https://www.businesswire.com/news/home/20240103872274/en/Maze-Therapeutics-to-Present-at-the-42nd-Annual-J.P.-Morgan-Healthcare-Conference"  
[X Link](https://x.com/MazeInBiotech/status/1742547383769022766)  2024-01-03T14:04Z [---] followers, [---] engagements


"During #JPM24 our CEO caught up with @BiotechTVHQ's @BradLoncar to share progress from our pipeline of genetically targeted medicines including our lead program in APOL1 #kidneydisease. (1/2) https://www.biotechtv.com/post/maze-therapeutics-january-8-2024 https://www.biotechtv.com/post/maze-therapeutics-january-8-2024"  
[X Link](https://x.com/MazeInBiotech/status/1744826238403748188)  2024-01-09T20:59Z [---] followers, [---] engagements


"We are proud to announce that we have completed an exclusive worldwide license agreement with @SHIONOGI_JP for the rights to MZE001 an investigational oral glycogen synthase [--] (GYS1) inhibitor that aims to address #Pompedisease. Read more here: https://www.shionogi.com/us/en/news/2024/05/Shionogi-Co-Ltd-and-Maze-Therapeutics-Inc-Announce-Exclusive-Worldwide-License-Agreement-for-MZE001-a-Novel-Therapeutic-Candidate-for-the-Treatment-of-Pompe-Disease.html"  
[X Link](https://x.com/MazeInBiotech/status/1788910756555108412)  2024-05-10T12:35Z [---] followers, [----] engagements


"Today we reported financial results for the second quarter ended June [--] [----] highlighting recent program progress and anticipated milestones. Read the full announcement here: https://ir.mazetx.com/news-releases/news-release-details/maze-therapeutics-reports-second-quarter-2025-financial-results https://ir.mazetx.com/news-releases/news-release-details/maze-therapeutics-reports-second-quarter-2025-financial-results"  
[X Link](https://x.com/MazeInBiotech/status/1955360149490766016)  2025-08-12T20:06Z [---] followers, [---] engagements


"Were looking forward to connecting at several upcoming investor conferences where members of the Maze leadership team will be participating in fireside chats. See todays announcement for details: https://ir.mazetx.com/news-releases/news-release-details/maze-therapeutics-participate-four-upcoming-investor-conferences https://ir.mazetx.com/news-releases/news-release-details/maze-therapeutics-participate-four-upcoming-investor-conferences"  
[X Link](https://x.com/anyuser/status/1985680162206228971)  2025-11-04T12:06Z [---] followers, [--] engagements


"We reported financial results for the third quarter ended September [--] [----] highlighting recent progress and business updates. Read the full announcement here: https://ir.mazetx.com/news-releases/news-release-details/maze-therapeutics-reports-third-quarter-2025-financial-results https://ir.mazetx.com/news-releases/news-release-details/maze-therapeutics-reports-third-quarter-2025-financial-results"  
[X Link](https://x.com/anyuser/status/1986790485726224870)  2025-11-07T13:38Z [---] followers, [---] engagements


"Our CEO and President R&D/CMO will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference on September [--]. A live webcast of the presentation will be available in the news & press section of our website. https://www.businesswire.com/news/home/20230921794593/en/Maze-Therapeutics-to-Participate-in-the-2023-Cantor-Fitzgerald-Global-Healthcare-Conference https://www.businesswire.com/news/home/20230921794593/en/Maze-Therapeutics-to-Participate-in-the-2023-Cantor-Fitzgerald-Global-Healthcare-Conference"  
[X Link](https://x.com/MazeInBiotech/status/1706304230355616064)  2023-09-25T13:46Z [---] followers, [---] engagements


"We are pleased to announcethe initiation of our Phase [--] trial of MZE829. MZE829 is an oral small molecule APOL1 inhibitor designed to block APOL1 pore function and ameliorate manifestations of APOL1 #kidneydisease. (1/2)"  
[X Link](https://x.com/MazeInBiotech/status/1735292610804084794)  2023-12-14T13:36Z [---] followers, [----] engagements


"We're thrilled to announce positive clinical results from the Phase [--] healthy volunteer study of MZE782 an oral small moleculeSLC6A19 inhibitor. MZE782 has potential to be a best-in-class therapy for patients with #phenylketonuria (PKU) an inherited metabolic disorder and a first-in-class therapyfor patients with chronic #kidneydisease. Read the full announcement: https://ir.mazetx.com/news-releases/news-release-details/maze-therapeutics-announces-positive-first-human-results-phase-1 https://twitter.com/i/web/status/1966107335241171042"  
[X Link](https://x.com/MazeInBiotech/status/1966107335241171042)  2025-09-11T11:51Z [---] followers, [---] engagements


"Welcome Herv Hoppenot as Chairman of our Board of Directors succeeding Charles Homcy M.D. who will remain on the Board. Hervs decades of experience will be invaluable as we approach major milestones in [----]. https://ir.mazetx.com/news-releases/news-release-details/maze-therapeutics-appoints-industry-veteran-herve-hoppenot https://ir.mazetx.com/news-releases/news-release-details/maze-therapeutics-appoints-industry-veteran-herve-hoppenot"  
[X Link](https://x.com/anyuser/status/1975154901836849626)  2025-10-06T11:03Z [---] followers, [---] engagements


"We're excited to be at this years @ASNKidneys #KidneyWk This week we will present additional pharmacokinetic data from our Phase [--] clinical trial of MZE782 research supporting inhibition of SLC6A19 to slow disease progression in #chronickidneydisease anddata supporting the scientific foundation and therapeutic rationale for MZE829. Read more: https://ir.mazetx.com/news-releases/news-release-details/maze-therapeutics-present-additional-data-highlighting https://ir.mazetx.com/news-releases/news-release-details/maze-therapeutics-present-additional-data-highlighting"  
[X Link](https://x.com/anyuser/status/1986403778573082732)  2025-11-06T12:02Z [---] followers, [---] engagements


"On #PKUAwarenessDay Maze supports@NPKUA_info PKU patientsand families.We honor the #phenylketonuria community and recognize the strength resilience and advocacy of individuals and families navigating this rare metabolic disorder. At Maze were dedicated to advancing meaningful options for people living with PKU through our investigational program MZE782 an oral small-molecule targeting the solute transporter SLC6A19 designed with the potential to deliver a best-in-class therapy for individuals with PKU. Learn more about PKU and ways to support the community through @NPKUA_info http://npkua.org"  
[X Link](https://x.com/anyuser/status/1996217866404925625)  2025-12-03T14:00Z [---] followers, [---] engagements


"Our president head of research and development and chief medical officer Harold Bernstein M.D. Ph.D. recently shared the Maze story at the BioScience Forum a monthly gathering for the biotech community in the San Francisco Bay Area. We appreciated the opportunity to connect with peers and discuss Mazes mission and scientific approach including how our Compass platform leverages variant functionalization to design #precisionmedicines that account for the genetic drivers of https://www.biosf.org/ https://www.biosf.org/"  
[X Link](https://x.com/anyuser/status/2000962995854131489)  2025-12-16T16:15Z [---] followers, [---] engagements


"As we close out [----] were taking a moment to reflect on what has truly made it meaningful. This year was filled with important milestones deeper partnerships with the patient community and continued progress driven by science.Were grateful to everyone who has been part of this journey and excited for whats ahead in [----] https://twitter.com/i/web/status/2001294836830232592 https://twitter.com/i/web/status/2001294836830232592"  
[X Link](https://x.com/anyuser/status/2001294836830232592)  2025-12-17T14:14Z [---] followers, [---] engagements


"We look forward to participating in the@GuggenheimPtnrs Emerging Outlook: Biotech Summit [----] next week.A live webcast of the event will be available in the Investors section of our website and archived for [--] days following the presentation. Read more: https://ir.mazetx.com/news-releases/news-release-details/maze-therapeutics-participate-guggenheim-emerging-outlook https://ir.mazetx.com/news-releases/news-release-details/maze-therapeutics-participate-guggenheim-emerging-outlook"  
[X Link](https://x.com/anyuser/status/2019019073754153284)  2026-02-04T12:03Z [---] followers, [--] engagements


"On the Lets Talk About That podcast our CEO Jason Coloma sat down with @anirvan0419 to reflect on Mazes journey from its earliest days through its IPO. He also shared how Maze anticipates growing over the next several years and continuing to build for durable impact through its #precisionmedicine approach. Listen here: https://open.spotify.com/episode/7dCJGGR91SYMs14aGjfpivsi=rSYdxHRbS_CiM7eGCcCnVQ&nd=1&dlsi=d2fa5d6392f842d8 https://open.spotify.com/episode/7dCJGGR91SYMs14aGjfpivsi=rSYdxHRbS_CiM7eGCcCnVQ&nd=1&dlsi=d2fa5d6392f842d8"  
[X Link](https://x.com/anyuser/status/2021231967111434656)  2026-02-10T14:37Z [---] followers, [---] engagements


"In recognition of #BlackHistoryMonth we welcomed Maze patient advisory committee member and #APOL1 #kidneydisease warrior Sharron Rouse for a powerful discussion on how APOL1 advocacy groups can better support patients highlighting the importance of education community and patient voices. Hope begins with awareness and strong advocacy can transform the patient journey by empowering individuals strengthening communities and paving the way for meaningful change. Learn more about Sharron's patient advocacy group @kkidneys here: https://www.kindnessforkidneys.org/"  
[X Link](https://x.com/anyuser/status/2021989194055262699)  2026-02-12T16:46Z [---] followers, [--] engagements


"In recognition of #BlackHistoryMonth we welcomed Maze patient advisory committee member and #APOL1 #kidneydisease warrior Sharron Rouse for a powerful discussion on how APOL1 advocacy groups can better support patients highlighting the importance of education community and patient voices. Hope begins with awareness and strong advocacy can transform the patient journey by empowering individuals strengthening communities and paving the way for meaningful change. Learn more about Sharron's patient advocacy group @kkidneys here: https://www.kindnessforkidneys.org/"  
[X Link](https://x.com/anyuser/status/2021989194055262699)  2026-02-12T16:46Z [---] followers, [--] engagements


"On the Lets Talk About That podcast our CEO Jason Coloma sat down with @anirvan0419 to reflect on Mazes journey from its earliest days through its IPO. He also shared how Maze anticipates growing over the next several years and continuing to build for durable impact through its #precisionmedicine approach. Listen here: https://open.spotify.com/episode/7dCJGGR91SYMs14aGjfpivsi=rSYdxHRbS_CiM7eGCcCnVQ&nd=1&dlsi=d2fa5d6392f842d8 https://open.spotify.com/episode/7dCJGGR91SYMs14aGjfpivsi=rSYdxHRbS_CiM7eGCcCnVQ&nd=1&dlsi=d2fa5d6392f842d8"  
[X Link](https://x.com/anyuser/status/2021231967111434656)  2026-02-10T14:37Z [---] followers, [---] engagements


"We look forward to participating in the@GuggenheimPtnrs Emerging Outlook: Biotech Summit [----] next week.A live webcast of the event will be available in the Investors section of our website and archived for [--] days following the presentation. Read more: https://ir.mazetx.com/news-releases/news-release-details/maze-therapeutics-participate-guggenheim-emerging-outlook https://ir.mazetx.com/news-releases/news-release-details/maze-therapeutics-participate-guggenheim-emerging-outlook"  
[X Link](https://x.com/anyuser/status/2019019073754153284)  2026-02-04T12:03Z [---] followers, [--] engagements


"⚕@MazeInBiotech is committed to developing breakthrough precision medicines for patients living with renal cardiovascular and related metabolic diseases. 🎊 Proud to be your exchange partner $MAZE #NasdaqListed"  
[X Link](https://x.com/anyuser/status/2015910889480687896)  2026-01-26T22:13Z 773.4K followers, [----] engagements


"One year ago Maze took a major step forward with our debut as a public company. This week we celebrated that milestone and oursubsequentsuccess ringing the @NasdaqExchange opening bell in honor of our one-year #IPOanniversary.Wereproud of whatweve accomplished together and energized bywhatsahead as we continue to execute in dedication to transforming the lives of patients living with kidney and metabolic diseases. $MAZE https://twitter.com/i/web/status/2016894760871473286 https://twitter.com/i/web/status/2016894760871473286"  
[X Link](https://x.com/anyuser/status/2016894760871473286)  2026-01-29T15:22Z [---] followers, [---] engagements


"At #JPM26 Join us this morning at 8:15 a.m. PT for our presentation. Were looking forward to kicking off the new year at #JPM26. CEO Jason Coloma Ph.D. will present on Monday January [--] at 8:15 a.m. PT. A live webcast of the event will be available in the Investors section of our website and archived for [--] days following the presentation. https://t.co/AvZW35s4Ub Were looking forward to kicking off the new year at #JPM26. CEO Jason Coloma Ph.D. will present on Monday January [--] at 8:15 a.m. PT. A live webcast of the event will be available in the Investors section of our website and archived"  
[X Link](https://x.com/anyuser/status/2010710803230368075)  2026-01-12T13:49Z [---] followers, [---] engagements


"Were looking forward to kicking off the new year at #JPM26. CEO Jason Coloma Ph.D. will present on Monday January [--] at 8:15 a.m. PT. A live webcast of the event will be available in the Investors section of our website and archived for [--] days following the presentation. https://ir.mazetx.com/news-releases/news-release-details/maze-therapeutics-participate-44th-annual-jp-morgan-healthcare https://ir.mazetx.com/news-releases/news-release-details/maze-therapeutics-participate-44th-annual-jp-morgan-healthcare"  
[X Link](https://x.com/anyuser/status/2008206615925710896)  2026-01-05T15:59Z [---] followers, [---] engagements


"As we close out [----] were taking a moment to reflect on what has truly made it meaningful. This year was filled with important milestones deeper partnerships with the patient community and continued progress driven by science.Were grateful to everyone who has been part of this journey and excited for whats ahead in [----] https://twitter.com/i/web/status/2001294836830232592 https://twitter.com/i/web/status/2001294836830232592"  
[X Link](https://x.com/anyuser/status/2001294836830232592)  2025-12-17T14:14Z [---] followers, [---] engagements


"Our president head of research and development and chief medical officer Harold Bernstein M.D. Ph.D. recently shared the Maze story at the BioScience Forum a monthly gathering for the biotech community in the San Francisco Bay Area. We appreciated the opportunity to connect with peers and discuss Mazes mission and scientific approach including how our Compass platform leverages variant functionalization to design #precisionmedicines that account for the genetic drivers of https://www.biosf.org/ https://www.biosf.org/"  
[X Link](https://x.com/anyuser/status/2000962995854131489)  2025-12-16T16:15Z [---] followers, [---] engagements


"On #PKUAwarenessDay Maze supports@NPKUA_info PKU patientsand families.We honor the #phenylketonuria community and recognize the strength resilience and advocacy of individuals and families navigating this rare metabolic disorder. At Maze were dedicated to advancing meaningful options for people living with PKU through our investigational program MZE782 an oral small-molecule targeting the solute transporter SLC6A19 designed with the potential to deliver a best-in-class therapy for individuals with PKU. Learn more about PKU and ways to support the community through @NPKUA_info http://npkua.org"  
[X Link](https://x.com/anyuser/status/1996217866404925625)  2025-12-03T14:00Z [---] followers, [---] engagements


"We enjoyed sharing Mazes progress and connecting with the kidney community at @ASNKidney's #KidneyWk this year. It was inspiring to join those who share a commitment to advancing care for people living with #kidneydisease. While in the area we also participated in the @nkf Houston #KidneyWalk joining patients families and supporters to raise awareness. Were grateful for the meaningful conversations and energized by the shared dedication across the field"  
[X Link](https://x.com/anyuser/status/1989032801245770202)  2025-11-13T18:09Z [---] followers, [---] engagements


"We reported financial results for the third quarter ended September [--] [----] highlighting recent progress and business updates. Read the full announcement here: https://ir.mazetx.com/news-releases/news-release-details/maze-therapeutics-reports-third-quarter-2025-financial-results https://ir.mazetx.com/news-releases/news-release-details/maze-therapeutics-reports-third-quarter-2025-financial-results"  
[X Link](https://x.com/anyuser/status/1986790485726224870)  2025-11-07T13:38Z [---] followers, [---] engagements


"We're excited to be at this years @ASNKidneys #KidneyWk This week we will present additional pharmacokinetic data from our Phase [--] clinical trial of MZE782 research supporting inhibition of SLC6A19 to slow disease progression in #chronickidneydisease anddata supporting the scientific foundation and therapeutic rationale for MZE829. Read more: https://ir.mazetx.com/news-releases/news-release-details/maze-therapeutics-present-additional-data-highlighting https://ir.mazetx.com/news-releases/news-release-details/maze-therapeutics-present-additional-data-highlighting"  
[X Link](https://x.com/anyuser/status/1986403778573082732)  2025-11-06T12:02Z [---] followers, [---] engagements


"Were looking forward to connecting at several upcoming investor conferences where members of the Maze leadership team will be participating in fireside chats. See todays announcement for details: https://ir.mazetx.com/news-releases/news-release-details/maze-therapeutics-participate-four-upcoming-investor-conferences https://ir.mazetx.com/news-releases/news-release-details/maze-therapeutics-participate-four-upcoming-investor-conferences"  
[X Link](https://x.com/anyuser/status/1985680162206228971)  2025-11-04T12:06Z [---] followers, [--] engagements


"Our CEO Jason Coloma joined @SullyCNBC on @CNBCs@PowerLunch to discuss Mazes recent progress and how were translating human genetics into new therapies across our pipeline. Chronic kidney disease remains a devastating condition with limited treatment options affecting millions of patients and families worldwide. At Maze were committed to advancing novel #smallmolecule #precisionmedicines designed to address the underlying drivers of #kidneydisease and metabolic disorders in meaningful ways. Watch the full interview:"  
[X Link](https://x.com/anyuser/status/1983278715539743168)  2025-10-28T21:04Z [---] followers, [---] engagements


"Welcome Herv Hoppenot as Chairman of our Board of Directors succeeding Charles Homcy M.D. who will remain on the Board. Hervs decades of experience will be invaluable as we approach major milestones in [----]. https://ir.mazetx.com/news-releases/news-release-details/maze-therapeutics-appoints-industry-veteran-herve-hoppenot https://ir.mazetx.com/news-releases/news-release-details/maze-therapeutics-appoints-industry-veteran-herve-hoppenot"  
[X Link](https://x.com/anyuser/status/1975154901836849626)  2025-10-06T11:03Z [---] followers, [---] engagements


"We recently joined the Tampa Bay #KidneyWalk hosted by the @nkf to help raise awareness and support for the millions of people impacted by #kidneydisease"  
[X Link](https://x.com/anyuser/status/1973021952077111654)  2025-09-30T13:47Z [---] followers, [---] engagements


"Walking alongside patients caregivers and advocates was a powerful reminder of why were committed to advancing science and developing potential therapies that can make a difference in kidney health including conditions such as #APOL1-mediated kidney disease"  
[X Link](https://x.com/anyuser/status/1973021955239612420)  2025-09-30T13:47Z [---] followers, [---] engagements


"We are pleased to announce an oversubscribed private placement of $150M today to further advance our pipeline of small molecule precision medicines for patients with kidney and metabolic diseases. Read the full announcement: https://ir.mazetx.com/news-releases/news-release-details/maze-therapeutics-announces-oversubscribed-1500-million-private https://ir.mazetx.com/news-releases/news-release-details/maze-therapeutics-announces-oversubscribed-1500-million-private"  
[X Link](https://x.com/anyuser/status/1966107453642183077)  2025-09-11T11:52Z [---] followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing